Collaborative team to progress novel USP30 DUB inhibitors to develop potential therapies for Parkinson’s disease  CAMBRIDGE, UK – 12 October 2021 – Mission Therapeutics (“Mission”), a drug discovery and development company focused on treating mitochondrial diseases, fibrosis and neurodegenerative disorders by selectively inhibiting deubiquitylating enzymes (DUBs), announced today that it has been awarded a Therapeutic […]

Mission receives $20 million milestone payment CAMBRIDGE, UK – 9 August 2021 – Mission Therapeutics (“Mission”), a drug discovery and development company focused on targeting the ubiquitin pathway, and AbbVie (“AbbVie”)(NYSE: ABBV) today announced progression of selected deubiquitylating enzyme (DUB) targets into the next phase of research in their neurodegenerative disease collaboration. In the second […]

CAMBRIDGE, UK – 2 June 2021 – Mission Therapeutics (“Mission”), a drug discovery and development company focused on selectively inhibiting deubiquitylating enzymes (DUBs), has announced today that Paul Thompson, Chief Scientific Officer (CSO), will present at the upcoming Next Wave in Neurodegeneration Investor event (3 June), as part of the UBS Innovation Series. Paul will […]

CAMBRIDGE, UK– 26 April 2021 – Mission Therapeutics (“Mission”), a drug discovery and development company focused on selectively inhibiting deubiquitylating enzymes (DUBs), has announced today that Paul Thompson, Chief Scientific Officer, will present at the Mitochondria-Targeted Drug Development Digital Summit (27-29 April). Paul will present a seminar titled: USP30 Inhibitors: Releasing the Brakes to Improve […]

CAMBRIDGE, UK– 25 March 2021 – Mission Therapeutics (“Mission”), a drug discovery and development company focused on selectively inhibiting deubiquitylating enzymes (DUBs), has nominated the first two development candidates from its in-house USP30 inhibitor program. USP30 inhibitor candidates MTX652 and MTX114 will be advanced through preclinical good laboratory practice (GLP) toxicology studies during 2021, with […]